El nostre pipeline
Última actualizació, juliol 2022.
Molecule / Project
|
Indication
|
Expected Launch
|
Preclinical Phase | Phase I | Phase II | Phase III | Under Registration | Geography |
---|---|---|---|---|---|---|---|---|
Lebrikizumab | Atopic dermatitis | Late 2023 |
|
|||||
Tirbanibulin Extended label |
Actinic keratosis | US 2024 / EU 2026 |
|
|||||
Sarecycline | Acne | 2024 |
|
|||||
Efinaconazole | Onychomycosis | 2023 |
|
|||||
Anti-IL-1RAP mAb | Autoinmune dermatology | TBD |
|
|||||
IL-2 mu Fc | Autoinmune dermatology | TBD |
|
* Worldwide ex-Greater China